Cargando…

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. Dacomiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poels, Kamrine E., Schoenfeld, Adam J., Makhnin, Alex, Tobi, Yosef, Wang, Yuli, Frisco-Cabanos, Heidie, Chakrabarti, Shaon, Shi, Manli, Napoli, Chelsi, McDonald, Thomas O., Tan, Weiwei, Hata, Aaron, Weinrich, Scott L., Yu, Helena A., Michor, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211846/ https://www.ncbi.nlm.nih.gov/pubmed/34140482 http://dx.doi.org/10.1038/s41467-021-23912-4

Ejemplares similares

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2022)

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
por: Cabanos, Heidie Frisco, et al.
Publicado: (2021)

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
por: Li, Hong-Shuai, et al.
Publicado: (2021)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Shen, Qian, et al.
Publicado: (2021)

Hidden heterogeneity and circadian-controlled cell fate inferred from single cell lineages
por: Chakrabarti, Shaon, et al.
Publicado: (2018)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
por: Zhang, Hui, et al.
Publicado: (2022)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
por: Stein, Shayna, et al.
Publicado: (2018)

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
por: Tamura, Shuzo, et al.
Publicado: (2018)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
por: Wilson, George D., et al.
Publicado: (2020)

Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry
por: Yamamoto, Yutaro, et al.
Publicado: (2019)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Tumor growth inhibition modeling to support the starting dose for dacomitinib
por: Fostvedt, Luke K., et al.
Publicado: (2022)

Stimulus schedules : the t-T Systems
por: Schoenfeld, William N., 1915-
Publicado: (1972)

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells
por: Xu, Lei, et al.
Publicado: (2021)

Drug-induced liver injury associated with dacomitinib: A case report
por: Wang, Xuanxuan, et al.
Publicado: (2022)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

On the Validity of Using Increases in 5-Year Survival Rates to Measure Success in the Fight against Cancer
por: Maruvka, Yosef E., et al.
Publicado: (2014)

Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma
por: Randles, Amanda, et al.
Publicado: (2021)

Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report
por: Qiao, Fei, et al.
Publicado: (2022)

Histomorphological and Immunohistochemical Study of Dacomitinib-Induced Ileal Mucositis in Rats with the Possible Protection by Baicalin
por: Kandeel, Samah, et al.
Publicado: (2022)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Stochastic Tunneling of Two Mutations in a Population of Cancer Cells
por: Haeno, Hiroshi, et al.
Publicado: (2013)

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
por: Endersby, Raelene, et al.
Publicado: (2018)

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
por: Zugazagoitia, Jon, et al.
Publicado: (2017)

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
por: Kim, Hyo Song, et al.
Publicado: (2015)

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib
por: Ruiz-Garcia, Ana, et al.
Publicado: (2020)

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase
por: Jathal, Maitreyee K., et al.
Publicado: (2019)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
por: Lavacchi, Daniele, et al.
Publicado: (2019)

Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2020)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
por: Morita, Ayako, et al.
Publicado: (2021)

A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
por: Alossaimi, Manal A., et al.
Publicado: (2023)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2015)

Investigation of dacomitinib on reducing cell necrosis and enhancing cell apoptosis in C6 glioma rat model by MRI
por: Chen, Wang-Sheng, et al.
Publicado: (2019)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
por: Li, Yibin, et al.
Publicado: (2022)

A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report
por: Zhou, Tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7id69ppvkkdtocejgt29jslg8r